http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 06:52:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Palvella+Therapeutics+%28PVLA%29/26797916.html <p>H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $270.00 price target on Palvella Therapeutics (NASDAQ: PVLA).</p><p>The analyst commented: "Yesterday, PVLA closed down 21% compared to the previous weeks close, which we believe was an overreaction to the updated corporate deck published last Tuesday stating that the FDA decided in July 2026 not to grant Breakthrough Therapy Designation (BTD) for cVM at this time. While this is a disappointing update, we do not believe it is cause for concern. PVLA plans to resubmit the BTD request with a stronger package that includes TOVIA patient interviews and 24-week data (see http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Palvella+Therapeutics+%28PVLA%29/26797916.html Wed, 22 Jul 2026 06:52:24 -0400 PVLA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jul+15++Filed+by%3A+Goin+Kathleen/26784352.html si-local-file:///var/storage/secattach/20260717/26784352.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jul+15++Filed+by%3A+Goin+Kathleen/26784352.html Fri, 17 Jul 2026 16:05:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jul+15++Filed+by%3A+Goin+Kathleen/26784352.html si-local-file:///var/storage/secattach/20260717/26784352.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jul+15++Filed+by%3A+Goin+Kathleen/26784352.html Fri, 17 Jul 2026 16:05:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++144++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Goin+Kathleen/26774390.html si-local-file:///var/storage/secattach/20260715/26774390.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Goin+Kathleen/26774390.html Wed, 15 Jul 2026 16:20:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++144++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Goin+Kathleen/26774390.html si-local-file:///var/storage/secattach/20260715/26774390.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Goin+Kathleen/26774390.html Wed, 15 Jul 2026 16:20:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jul+14/26768831.html si-local-file:///var/storage/secattach/20260714/26768831.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jul+14/26768831.html Tue, 14 Jul 2026 16:49:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jul+14/26768831.html si-local-file:///var/storage/secattach/20260714/26768831.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jul+14/26768831.html Tue, 14 Jul 2026 16:49:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29++Filed+by%3A+Pauls+Matthew/26720637.html si-local-file:///var/storage/secattach/20260701/26720637.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29++Filed+by%3A+Pauls+Matthew/26720637.html Wed, 01 Jul 2026 16:06:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29++Filed+by%3A+Pauls+Matthew/26720637.html si-local-file:///var/storage/secattach/20260701/26720637.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29++Filed+by%3A+Pauls+Matthew/26720637.html Wed, 01 Jul 2026 16:06:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29++Filed+by%3A+Pauls+Matthew/26720615.html si-local-file:///var/storage/secattach/20260701/26720615.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29++Filed+by%3A+Pauls+Matthew/26720615.html Wed, 01 Jul 2026 16:05:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29++Filed+by%3A+Pauls+Matthew/26720615.html si-local-file:///var/storage/secattach/20260701/26720615.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29++Filed+by%3A+Pauls+Matthew/26720615.html Wed, 01 Jul 2026 16:05:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29/26709615.html si-local-file:///var/storage/secattach/20260630/26709615.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29/26709615.html Tue, 30 Jun 2026 07:37:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29/26709615.html si-local-file:///var/storage/secattach/20260630/26709615.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+29/26709615.html Tue, 30 Jun 2026 07:37:00 -0400 O.00285300 PVLA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html <p>Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.</p> <p>Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of http://www.streetinsider.com/Board+Changes/Palvella+Therapeutics+adds+Matt+Pauls+to+its+board+of+directors/26709557.html Tue, 30 Jun 2026 07:30:35 -0400 A.00434381 A.05964552 A.06822034 A.17548246 A.32106011 A.50114007 A.50216931 INSM O.00285300 O.03220543 O.17303445 O.20026344 O.21682530 O.25000470 O.38120420 O.60639541 PVLA SVRA